Navigation Links
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
Date:8/25/2009

reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Aug. 25, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
2. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
3. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Medarex to Receive Milestone Payment from Amgen
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Reportlinker.com announces that a ... catalogue: mHealth and Home Monitoring – ... Executive summary mHealth can ... better outcomes, decreased costs and improved sustainability of ... is still in an early stage, but on ...
(Date:7/30/2014)... brand ambassadors Fred Funk and Hal Sutton ... near Minneapolis, MN , which begins Friday at ... the official joint replacement products company of the PGA TOUR and ... through Sunday, August 3 rd , fans will be able to ... in the Pioneer Press Expo tent located near the clubhouse and ...
(Date:7/30/2014)... Calif. , July 30, 2014 Silicon ... released a study today that examines the ... and medical device companies.  According to the annual report ... the biggest potential returns since SVB started tracking the ... of the IPO.  Built on solid healthcare M&A activity ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
... findings presented today show that CONCERTA® (OROS® methylphenidate ... medication with data that demonstrate a significant treatment ... 12.5 hours in children with Attention Deficit Hyperactivity ... medical condition characterized by inattention, hyperactivity and impulsivity(1) ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... announced unaudited financial results for the three months ended ... September 30, 2009 , As of September 30, ... equivalents and an additional $50.9 million in investment securities, ...
Cached Medicine Technology:CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 2CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 3CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 4CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 5CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 6CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... to help their preschooler shed excess pounds may want to ... whose parents joined them in a supervised behavioral modification program ... a traditional child-only program (an average difference of about four ... almost 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... from the Church of Scientology of Denmark have joined ... distribution of Truth About Drugs education booklets. ... the famous Copenhagen walking street. Popular with tourists ... some quarter of a million people stroll down the ... activities are part of a coordinating effort by Scientologists ...
(Date:7/30/2014)... to fuel cancer as well as evolutionary changes in ... that occur randomly throughout the genome. , However, recent ... formation of multiple mutations that arise simultaneously and in ... mutations are frequently found in regions where chromosomal rearrangements ... Cell Reports , may one day lead to ...
(Date:7/30/2014)... Lexington, MA (PRWEB) July 30, 2014 ... provider of authentication, access management and secure communications ... Imprivata OneSign ® is the most widely ... using McKesson Paragon or Horizon electronic medical records ... (an increase of about 11 percent in the ...
(Date:7/30/2014)... IN (PRWEB) July 30, 2014 ... the opening of its new Carmel office on July ... staff will finally be moving to the state-of-the-art suite, ... cozy and innovative space will allow for one-on-one patient ... cosmetic surgery experience. , Dr. Hamilton’s new office-suite ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2
... , , PASADENA, ... AIMM) today announced its licensee, BioMS Medical Corp., and ... meet the primary endpoint of delaying disease progression, as ... the two-year Phase III trial in patients with secondary ...
... EATONTOWN, N.J., July 30 Osteotech, Inc. (Nasdaq: ... for regenerative healing, announced today that its management team is scheduled ... Healthcare Conference at the Millennium Broadway Hotel in New York on ... A live, listen-only webcast of the presentation can be ...
... , , , , ... Corp. (Nasdaq: WBMD ) today announced financial results for the three ... to deliver strong results again this quarter. WebMD,s advertising revenue grew by 18% ... companies in the health and wellness markets," said Wayne Gattinella, President and CEO. ...
... , WASHINGTON, July 30 An estimated 700,100 residents ... a House health reform bill, according to state-specific analysis ... released this week by The Heritage Foundation . ... Lewin Group , a highly respected health care policy and ...
... NOVATO, Calif., July 30, BioMarin Pharmaceutical Inc. (Nasdaq: ... has issued patents covering stable tablet formulation and the approved once ... phenylketonuria (PKU). The patent for stable tablet formulation expires in ... in 2024. , , "We believe the issuance ...
... researchers say , THURSDAY, July 30 (HealthDay News) -- ... vaccine activates the immune system against the virus appear ... study finds. , According to Dutch researchers led by ... immune system goes on alert against the seasonal flu ...
Cached Medicine News:Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:WebMD Announces Second Quarter Financial Results 2Health News:WebMD Announces Second Quarter Financial Results 3Health News:WebMD Announces Second Quarter Financial Results 4Health News:WebMD Announces Second Quarter Financial Results 5Health News:WebMD Announces Second Quarter Financial Results 6Health News:WebMD Announces Second Quarter Financial Results 7Health News:WebMD Announces Second Quarter Financial Results 8Health News:WebMD Announces Second Quarter Financial Results 9Health News:WebMD Announces Second Quarter Financial Results 10Health News:WebMD Announces Second Quarter Financial Results 11Health News:WebMD Announces Second Quarter Financial Results 12Health News:WebMD Announces Second Quarter Financial Results 13Health News:WebMD Announces Second Quarter Financial Results 14Health News:WebMD Announces Second Quarter Financial Results 15Health News:WebMD Announces Second Quarter Financial Results 16Health News:WebMD Announces Second Quarter Financial Results 17Health News:WebMD Announces Second Quarter Financial Results 18Health News:WebMD Announces Second Quarter Financial Results 19Health News:Thousands of Nebraskans Could Lose Private Insurance, Study Shows 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 3Health News:Flu Shot May Be Less Effective in Those With Lupus 2
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: